• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Belite Bio Inc

    5/13/25 9:23:28 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLTE alert in real time by email
    6-K 1 tm2514797d1_6k.htm FORM 6-K

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER 

    PURSUANT TO RULE 13a-16 OR 15b-16 OF 

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2025

     

    Commission File Number: 001-41359

     

    Belite Bio, Inc 

    (Exact name of registrant as specified in its charter)

     

    Not Applicable 

    (Translation of Registrant´s name into English)

     

    12750 High Bluff Drive Suite 475, 

    San Diego, CA 92130 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F x   Form 40-F ¨

     

     

     

     

     

    On May 13, 2025, Belite Bio, Inc issued a press release entitled “Belite Bio Reports First-Quarter 2025 Financial Results and Provides Corporate Update”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    EXHIBIT INDEX

     

    Exhibit 99.1 — Press Release

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Belite Bio, Inc
         
      By: /s/ Yu-Hsin Lin
      Name: Yu-Hsin Lin
      Title: Chief Executive Officer and Chairman

      

    Date: May 13, 2025

     

     

     

     

    Get the next $BLTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLTE

    DatePrice TargetRatingAnalyst
    12/14/2023$60.00Buy
    Maxim Group
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    7/26/2023$25.00Outperform
    SVB Securities
    8/1/2022$58.00Buy
    H.C. Wainwright
    More analyst ratings

    $BLTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)DSMB also recommended the Company submit the interim data for further regulatory review for drug approvalA pivotal global Phase 3 trial (PHOENIX) of Tinlarebant in geographic atrophy (GA) patients is ongoing with 464 of targeted 500 subjects enrolledRaised $15 million in gross proceeds in a registered direct offering on February 5, 2025Conference call and webcast on Wednesday, May

      5/13/25 9:00:36 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

      SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that CSO, Dr. Nathan L. Mata will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on May 15, 2025. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors. DATE: May 15th TIME: 12:30 pm ET LINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company quest

      5/12/25 8:35:00 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio to Participate in Four Upcoming Investor Conferences

      SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows: Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual) May 15, 2025, at 12:30 pm ET, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (New York, NY) May 20, 2025, at 5:00 pm ET, fireside chat Stifel 2025 Ophthalmology Forum (Vir

      5/12/25 8:00:00 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    SEC Filings

    See more
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      5/13/25 9:23:28 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      4/15/25 4:00:44 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      3/28/25 4:00:21 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Leadership Updates

    Live Leadership Updates

    See more
    • Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

      Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar

      9/1/24 8:00:00 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Belite Bio with a new price target

      Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00

      12/14/23 8:06:18 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Belite Bio with a new price target

      Cantor Fitzgerald initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $43.00

      7/28/23 7:14:28 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on Belite Bio with a new price target

      SVB Securities initiated coverage of Belite Bio with a rating of Outperform and set a new price target of $25.00

      7/26/23 7:15:36 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Financials

    Live finance-specific insights

    See more

    $BLTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

      Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,

      11/12/24 1:00:25 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

      Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET

      11/13/23 8:15:47 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

      In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease ("STGD1") trial ("LBS-008-CT02"), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjectsA continued trend of slowing expansion of autofluorescence was observed and the growth rate of incident atrophic retinal lesions was reduced with Tinlarebant in LBS-008-CT02 compared to a natural history study of the disease ("ProgStar")Stabilization of visual acuity with no significant loss and no clinically significant changes in retinal thickness observed over 18 months of treatment with Tinlarebant in LBS-008-CT0258 subjects have been enrolled in the pivotal Phase 3 "DRAGON" trial eva

      5/10/23 7:58:59 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Belite Bio Inc

      SC 13G - BELITE BIO, INC (0001889109) (Subject)

      2/12/24 9:08:25 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Belite Bio Inc

      SC 13G - BELITE BIO, INC (0001889109) (Subject)

      2/12/24 8:40:46 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Belite Bio Inc

      SC 13G - BELITE BIO, INC (0001889109) (Subject)

      2/15/23 1:36:20 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care